NCT06204094View on ClinicalTrials.gov

Node-sparing Radiotherapy Combined with Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2028

Conditions
Locally Advanced Rectal Cancer
Interventions
RADIATION

node-sparing short-course radiotherapy

5Gy\*5d, radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes

DRUG

Sintilimab

200mg intravenous infusion d1 of each cycle\*8cycles

DRUG

Capecitabine

1000mg/m2, PO, BID, d1-14 of each cycle\*8cycles

DRUG

Oxaliplatin

130mg/m2, intravenous infusion,d1 of each cycle\*8cycles

PROCEDURE

TME surgery

laparoscopic or robotic TME surgery for non-cCR patients

PROCEDURE

watch and wait

WW for cCR patients

Trial Locations (1)

0579

RECRUITING

Zhejiang University Affiliated Jinhua Hospital, Jinhua

All Listed Sponsors
lead

Jinhua Central Hospital

OTHER